A5002813173- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Colorectal Cancer Surgical Treatments
- Gastric Cancer Management and Outcomes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal Cancer Screening and Detection
- Renal cell carcinoma treatment
- Genetic factors in colorectal cancer
- Brain Metastases and Treatment
- Lung Cancer Treatments and Mutations
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Esophageal Cancer Research and Treatment
- Venous Thromboembolism Diagnosis and Management
- Pediatric Hepatobiliary Diseases and Treatments
- Mechanisms of cancer metastasis
- Lung Cancer Research Studies
- Cancer Mechanisms and Therapy
- Neutropenia and Cancer Infections
- Clinical practice guidelines implementation
- Cancer Diagnosis and Treatment
- Gestational Trophoblastic Disease Studies
Hospital Agioi Anargyroi
2013-2023
Hellenic Cooperative Oncology Group
2012-2020
Senologic Hellenic Society
2020
Castle Hill Hospital
2011
Princess Royal Hospital
2004-2008
St George's Hospital
2007
National and Kapodistrian University of Athens
2007
University of Hull
2005
More than half of patients with KRAS-wild type advanced colorectal cancer (CRC) fail anti-EGFR monoclonal antibodies. We studied EGFR-axis messenger RNA (mRNA) expression and RAS, RAF, PIK3CA mutations in order to identify additional biomarkers cetuximab efficacy. Previously genotyped (KRAS, NRAS, BRAF, mutations) formalin-fixed paraffin-embedded tumour biopsies 226 cetuximab-treated CRC (1st 3rd line therapy) were assessed for mRNA epidermal growth factor receptor (EGFR) its ligands EGF,...
The aim was to compare two standard chemotherapy regimens combined with bevacizumab as first-line treatment in patients metastatic colorectal cancer. Patients previously untreated for disease were randomized in: group A (irinotecan, capecitabine, bevacizumab, every 3 weeks; XELIRI-bevacizumab) and B leucovorin, fluorouracil, 2 FOLFIRI-bevacizumab). Primary endpoint progression-free survival (PFS). Plasma concentrations of nitric oxide, osteopontin, TGF-β1 VEGF-A measured at baseline during...
The aim of the trial was to compare two active adjuvant chemotherapy regimens in patients with early stage colorectal cancer (CRC).Patients were assigned oxaliplatin, leucovorin and 5-FU for 12 cycles (group A, FOLFOX6) or oxaliplatin capecitabine eight B, CAPOX). Primary endpoint disease-free survival (DFS). Tumors classified as mismatch repair proficient (pMMR) deficient (dMMR) according MLH1, PMS2, MSH2 MSH6 protein expression. KRAS exon BRAF V600E mutational status also assessed.Between...
Data on the effectiveness and safety of approved SARS-CoV-2 vaccines in cancer patients are limited. This observational, prospective cohort study investigated humoral immune response to vaccination 232 from 12 HeCOG-affiliated oncology departments compared 100 healthcare volunteers without known active cancer. The seropositivity rate was measured 2–4 weeks after two vaccine doses, by evaluating neutralising antibodies against spike protein using a commercially available immunoassay....
In rectal cancer management, accurate staging by magnetic resonance imaging, neo-adjuvant treatment with the use of radiotherapy, and total mesorectal excision have resulted in remarkable improvement oncological outcomes. However, there is substantial discrepancy therapeutic approach failure to adhere international guidelines among different Greek-Cypriot hospitals. The present aim aid multidisciplinary management cancer, considering both local special characteristics our healthcare system...
Conventional treatment for brain metastases (BM) is whole-brain radiotherapy (WBRT). Efficacy poor. It might be increased by a potent radiosensitiser such as gemcitabine which believed to cross the disrupted blood–brain barrier. Primary objective of this study was determine maximum tolerated dose (MTD) twice weekly given concurrently with WBRT. Patients BM from carcinoma were included. The WBRT 30 Gys (10 daily fractions). Gemcitabine 2–4 h prior on days 1 and 8 first cohort patients then 1,...
Our aim was to determine the prevalence, prognostic and predictive role of germline pathogenic/likely pathogenic variants (P/LPVs) in cancer predisposing genes patients with pancreatic ductal adenocarcinoma (PDAC). Germline testing 62 susceptibility performed on unselected diagnosed from 02/2003 01/2020 PDAC, treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated Centers. The main endpoints were prevalence P/LPVs overall survival (OS). PDAC-associated homologous recombination...
To access the efficacy of chemotherapy plus radiofrequency ablation (RFA) as one line treatment in inoperable colorectal liver metastases.Eligible patients were included three Phase II studies. In first study percutaneous RFA was used followed by 6 cycles 5-fluorouracil, leucovorin and irinotecan combination (FOLFIRI) (adjunctive trial). other two, (FOLFIRI or oxaliplatin combination) up to 12 with offered responding (primary trials).Thirteen adjunctive trial 17 two. At inclusion they had...
Th ere is discrepancy and failure to adhere current international guidelines for the management of metastatic colorectal cancer (CRC) in hospitals Greece Cyprus.Th e aim present document provide a consensus on multidisciplinary metastastic CRC, considering both special characteristics our Healthcare System guidelines.Following discussion online communication among members an executive team chosen by Hellenic Society Medical Oncology (HeSMO), CRC disease was developed.Statements were...
We present the case of a patient with colon cancer who, while receiving bevacizumab, developed sinusoidal obstruction syndrome (veno-occlusive disease) (SOSVOD). Certain antitumour agents such as 6-mercaptopurine and 6-thioguanine have also been reported to initiate hepatic SOSVOD in isolated cases. There no reports so far correlating bevacizumab SOSVOD. A 77-year-old man was being treated oxaliplatin modified de Gramont regimen 5-fluorouracil for metastatic cancer. Bevacizumab (7.5 mg/kg)...